Wall Street analysts changed outlook on top names, including MCRB, SAFX. See analyst ratings page for full coverage.
Top Wall Street analysts changed their outlook on these top names.
For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
HC Wainwright & Co. analyst Matthew Keller initiated coverage on Seres Therapeutics Inc (NASDAQ:MCRB) with a Buy rating and announced a price target of $12.
Seres Therapeutics shares closed at $6.60 on Monday.
See how other analysts view this stock.
Top Wall Street analysts changed their outlook on top names. See upgrades, downgrades & initiations on analyst ratings page.…
Top Wall Street analysts change outlook on top names. See analyst ratings page for changes, including…
Top Wall Street analysts changed outlook on top names. See analyst ratings page for upgrades, downgrades, and initiations. Check…
Top Wall Street analysts changed outlook on top names. Find all rating changes on Benzinga's analyst ratings page. See analyst…
Top Wall Street analysts changed outlook on top names. See analyst ratings page for all changes. Analysts have mixed views on…
Analysts change outlook on top names. Check out ratings page for upgrades, downgrades, and initiations.
